[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100651699","outcomes-of-iliac-vein-stenting-with-dedicated-venous-stents-in-treatment-of-chronic-post-thrombotic-venous-ulcers-100651699",false,"NCT07762222","Outcomes of Iliac Vein Stenting With Dedicated Venous Stents in Treatment of Chronic Post-thrombotic Venous Ulcers","Inclusion Criteria:\n\n* Chronic non-healing venous ulcer associated with iliofemoral post-thrombotic syndrome.\n* CEAP clinical classification C6.\n* Iliofemoral post-thrombotic venous obstruction confirmed by appropriate venous imaging.\n* Age 18 years or older.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Nonthrombotic iliac vein lesion (NIVL).\n* Post-phlebitic femoropopliteal venous lesions with a patent iliac vein.\n* CEAP clinical classification other than C6.\n* Previous venous intervention.\n* Active pathological ulcer unrelated to post-thrombotic venous disease.\n* Life expectancy less than 2 years.\n* Pregnancy.\n* Known allergy to contrast media.\n* Contraindication to anesthesia.\n* Refusal to participate or inability to provide informed consent.","ALL","18 Years","70 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","Outcomes of iliac vein stenting with dedicated venous stents in treatment of chronic post-thrombotic venous ulcers Deep vein thrombosis (DVT) affects 1 to 3 individuals per 1000 annually. Among these patients, 20% to 50% may develop post-thrombotic syndrome (PTS), with the likelihood varying based on the extent and location of the thrombus. Notably, despite receiving anticoagulation therapy, 5% to 10% of patients may progress to severe PTS, potentially leading to the development of venous ulcers (Afsha Aurshina, 2018). Chronic venous obstruction (CVO) refers to the impediment of venous flow, typically resulting from either partial or complete blockage of the venous system. This obstruction leads to diminished venous flow and elevated pressure within the affected veins. CVO serves as a broad descriptor for various conditions, including post-thrombotic syndrome (PTS) and nonthrombotic iliac vein lesions (NIVLs). PTS commonly arises as a complication of deep vein thrombosis (DVT), with estimates indicating that up to 50% of patients diagnosed with iliofemoral DVT will develop PTS within two years following their initial diagnosis. (Mohammad E. Barbati, 2024)\n\nThe study aims to know the outcomes of iliac vein stenting with dedicated venous stenting in the treatment of post-thrombotic syndrome venous ulcer.\n\nType of Study: Prospective single arm cohort study\n\n* Study Setting: Ain Shams University hospitals\n* Study Period: 2 years with 6 months follow up\n* Sample Size: 20 patients.\n* Study Population Patients presenting to the outpatient clinic at Ain Shams University Hospitals with venous ulcers.\n* Study Tools\n\n  * 20 patients will be selected.\n  * Written informed consent.\n  * Full history taking, personal history , risk factors of DVT, presence of any medical illness , assessment of QOL based on CVIQ 20 - questionnaire, list of symptoms, sensations or types of discomfort that you may or may not be experiencing and which may make everyday life hard to bear to a greater or lesser extent.\n  * Clinical evaluation: based on revised Venous Clinical Severity Score rVCSS , Villalta score and CEAP classification . rVCSS includes 10 items, such as pain, varicose veins, oedema, skin pigmentation, inflammation, skin induration, number of active ulcers, ulcer size, duration of ulcer, and application of pressure therapy. Each item is scored from 0 to 3 according to the severity, and the total score is 30. A higher score indicates higher severity. And using villlata score It can be used to both diagnose and categories the severity of the condition. The Villalta score involves both the patient who grades the presence and severity (0-3 points) of five symptoms ( pain , cramps, heaviness, parasthesia and pruritus ) and and the physician who grades six clinical signs(Pre-tibial oedema, Hyper-pigmentation, Redness, Venous Ectasia, ain on calf compression, ulcers) (0-3 points) after examination of the lower limb. Also the clinical severity of the venous disease will be graded according to the clinical, etiological, anatomical, and pathophysiological (CEAP) scoring system, and assessment of venous ulcer assessment (by onset, course, duration, site, size, shape",[26,27,28,29],"Vascular","DVT - Deep Vein Thrombosis","Post Thrombotic Syndrome","Venous Ulcer of Leg",[31,32,33],"iliofemoral postthrombotic syndrome","venous ulcer","dedicated iliac venous stenting","RECRUITING","2026-08-08",{"date":37,"type":38},"2026-08-13","ACTUAL",{"date":40,"type":38},"2025-03-02",{"date":42,"type":20},"2027-01-01",{"name":44,"class":45},"Ain Shams University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100645202","ai-technologies-for-enhanced-and-celerated-high-field-wb-mri-100645202","NCT07678320","AI Technologies for Enhanced and Celerated High-Field WB-MRI","AITECH-MRI","Inclusion Criteria:\n\n* Consecutive adults (≥18 y.o.) admitted to the UO for W MRI for screening procedure.\n* Consecutive adult male patients (≥18 y.o.) admitted to the UO for WB-MRI for screening procedure and focus on prostate.\n\nExclusion Criteria:\n\n* refused to consent\n* claustrophobia\n* metal prosthesis potentially affecting image quality",true,{"count":56,"type":20},600,"OBSERVATIONAL","Single-center, cross-sectional observational study assessing the feasibility of advanced accelerated MRI sequences versus standard ones in terms of image quality, diagnostic reliability, and acquisition time.",[60,61,62,63,26],"Whole Body Imaging","Prostate","MRI","Lung",[62,65,66,67,26],"Whole Body","Accelerated Imaging","Prostate Imaging","NOT_YET_RECRUITING","2026-06-25",{"date":71,"type":38},"2026-07-01",{"date":71,"type":20},{"date":74,"type":20},"2029-05-01",{"name":76,"class":45},"IRCCS San Raffaele",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":54,"sex":15,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100609294","the-role-of-estrogen-and-testosterone-in-determining-brain-blood-flow-and-metabolic-regulation-in-humans-100609294","NCT07212712","The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans","Inclusion Criteria:\n\nThe investigators will recruit healthy young (18-40 years) males (n = 25) and females (n = 25). Females must be naturally cycling (i.e., no oral or hormonal contraceptives), not pregnant, and premenopausal. Participants must be normotensive (\\\u003C140\u002F90 mmHg \\& \\>90\u002F60 mmHg) and have no medical history of cerebrovascular, cardiopulmonary, cardiovascular, neuromuscular, and renal disease assessed by a study questionnaire. A recent physical examination (within 1 year of participation) from a family physician or a completed physical examination by the study doctor is required prior to participation. All subjects will sign an informed consent form prior to participation.\n\nParticipants will be excluded if they meet any of the following criteria:\n\n* Hypertensive (≥140\u002F90 mmHg) or hypotensive (≤90\u002F60 mmHg)\n* BMI ≥ 30 kg\u002Fm2\n* Fasting blood glucose ≥ 100 mg\u002FdL\n* Abnormal results on standard blood hematology tests (e.g., complete blood count, comprehensive metabolic panel)\n* Males with hypogonadism (total testosterone ≤ 262 ng\u002FdL, per Endocrine Society recommendations)\n* Any history of cerebrovascular, cardiopulmonary, cardiovascular, neuromuscular, or renal disease\n* Any liver dysfunction or disease\n* Taking any cardiovascular medications or medications that would interfere with study medications (e.g., strong organic anion transporting polypeptide 1B1 inhibitors)\n* Contraindications or sensitivities to study medications\n* Current eating disorder (defined as \\>2 on the 'SCOFF' questionnaire 67)\n* Current smokers\n* Females with an irregular menstrual cycle or any medical conditions affecting the menstrual cycle (normal cycle defined as 21-35 days from menstrual cycle diary)\n* Females who are pregnant (assessed with pregnancy test at screening and prior to starting medications), breastfeeding, or planning to conceive within 3 months\n* Females using hormonal birth control (Copper intrauterine devices \\[IUDs\\] will be allowed as they do not change systemic hormone levels)\n* Females who are peri- or postmenopausal (as determined by STRAW criteria 68)\n* History of hormone-sensitive cancers (i.e., breast, ovarian, uterine or prostate)\n* Z-score \\\u003C -2 as assessed with DXA scan (to determine risk of decrease in bone mineral density)\n* Assessed using the Center for Epidemiologic Studies Depression (CES-D) scale, participants with a score \\> 16 at screening unless otherwise approved by the study MD","18 Weeks","40 Weeks",{"count":86,"type":20},50,[23],"Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.",[90,91,92,93,26],"Cerebral Blood Flow","Cerebral Blood Flow Regulation","Sex Differences","Exercise","2026-02-06",{"date":96,"type":38},"2026-02-10",{"date":98,"type":20},"2026-04-01",{"date":100,"type":20},"2027-12-31",{"name":102,"class":45},"University of British Columbia"]